Increasing interlinks between prevalence of urticaria pigmentosa and eventual progression to debilitating forms of skin cancers is accelerating research for developing early stage diagnosis and therapeutics
Increasing interlinks between prevalence of urticaria pigmentosa and eventual progression to debilitating forms of skin cancers is accelerating research for developing early stage diagnosis and therapeutics
Fact.MR, Rockville MD: An ongoing study on the urticaria pigmentosa treatment market by market research firm Fact.MR has projected positive growth prospects for 2021. While sales decelerated moderately amid the COVID-19 pandemic, owing to redirection of healthcare spending to develop therapeutic approaches for eradicating the virus, concerns over possible impact of the pandemic amongst skin patients have helped sustain sales through 2020.
The National Center for Biotechnology Information advocates that urticaria pigmentosa is a manifestation of mastocytosis, occurring in 45% to 75% of the patients globally. Healthcare experts predict a lifetime prevalence rate of pigmentosa at about 20%. Furthermore, 80-90% of chronic urticaria cases are idiopathic in nature, with no previously documented cause or mechanism. Such trends are bolstering research initiatives to pinpoint the genesis and subsequent diagnosis of the disease.
Growth is further underpinned by patients seeking diagnosis to check for possible onset of melanoma. Studies undertaken during the previous decade established that 5% of mastocytosis patients developed skin cancer later on in their lives. As of 2018, there were nearly 300,000 new melanoma and over a million non-melanoma cases globally, as per estimates provided by the American Institute for Cancer Research. Hence, manufacturers are augmenting their research capabilities to discover new breakthroughs to mitigate urticaria pigmentosa prevalence, providing new revenue streams in the long-run.
“Prolific technological advancements in skin diagnostics has led to the emergence of highly advanced therapeutic approaches, prompting key urticaria pigmentosa treatment providers to leverage the same in their existing product portfolios. Partnerships with research and academic institutions are expected to increase so as to discover new breakthroughs in treating this malady,” remarks the Fact.MR analyst.
Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=3185
Key Takeaways from Fact.MR’s Urticaria Pigmentosa Study
- By product, anti-inflammatory drugs prescriptions are increasing, followed by skin creams
- Treatment across dermatology centers are poised to increase amid growing investments to foster specialized skincare
- Treatment for stage 0 melanoma, a possibility arising out of pigmentosa presence, to fuel sales across the US
- UK to witness a combination of clinical and psychological treatment of urticaria pigmentosa
- High incidence of mast cell activation syndrome is accelerating research for advanced therapeutics across Germany
- India to present lucrative growth opportunities amid increased genetic inheritance of pigmentosa leading to development of pharmaceutical products
Urticaria Pigmentosa Treatment Market- Prominent Drivers
- Growing public awareness regarding skin health is fostering advanced therapeutic developments, heightening growth prospects
- Possibility of skin cancer onset due to the presence of urticaria pigmentosa is prompting patients to seek timely diagnosis
- Nanoparticle injection based treatment is likely to generate credible future expansion opportunities
Urticaria Pigmentosa Treatment Market- Key Restraints
- Documented side effects arising out of histamine infused pigmentosa drugs is likely to hinder uptake
- Inadequate access to effective urticaria pigmentosa treatment approaches in developing countries is limiting market penetration
Discover more about the urticaria pigmentosa market with figures, data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/3185/pigmentosa-treatment-market
Competitive Landscape
Key players profiled by Fact.MR’s report include Cipla Limited, Centaur Pharmaceuticals, Sanofi SA, Pfizer Inc., Bayer AG, Zahravi Pharmaceutical Co., Johnson & Johnson Group and Novartis AG among others. Prominent expansion strategies involve introduction of novel therapeutic approaches, expansion of research & development capabilities and strategic collaborations, takeovers and mergers.
Additionally, government initiatives to spread awareness regarding the debilitating impacts of skin disorders is promoting accelerated research at the academic and institutional levels to find therapeutic breakthroughs. As a consequence, key market players are entering into partnerships to provide their expertise on oral and cutaneous drug delivery. Furthermore, they are sanctioning funds to initiate clinical trials in laboratories to test the efficacies of potential drug candidates.
More Insights on the Urticaria Pigmentosa Market
In its latest report, Fact.MR offers unbiased analysis of the global urticaria pigmentosa treatment market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product type (drugs and cream) and end-user (hospitals, specialty clinics, dermatology centers and beauty clinics) across seven major regions (North America, Latin America, Western Europe, Eastern Europe, APAC, Japan and Middle East & Africa).
Request more information about Report Methodology
https://www.factmr.com/connectus/sample?flag=RM&rep_id=3185
Explore Fact.MR’s Coverage on the Healthcare Domain
Medical Education Market: Fact.MR’s medical education market study sheds light on the prominent expansion dynamics expected to shape future growth of the landscape. Information on key segments’ prevalence across prominent geographies along with a detailed competitive landscape analysis provides a holistic overview of the overall scenario likely to pan out for the upcoming decade.
Microscopy Devices Market: A detailed assessment of the global microscopy devices market value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in Fact.MR’s extensive coverage on the subject. The report analyses potential expansion drivers and trends expected to prevail across prominent geographies in the forthcoming decade.
Ophthalmic Drugs Market: Fact.MR’s ophthalmic drugs market study delves into an incisive analysis of prominent expansion dynamics expected to outline the future expansion trajectory of the landscape for the forthcoming decade. A detailed competitive landscape embedded in the report provides a realistic outlook concerning the trends expected to present themselves throughout the market’s expansion journey.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Sudip Saha
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583